ASCO Annual Meeting | Conference

Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28th 2016

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Dr. Kaufman on Avelumab in Merkel Cell Carcinoma

July 28th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

Dr. van den Bent on Adjuvant Temozolomide in Anaplastic Glioma

July 27th 2016

Martin J. Van Den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherland, discusses the results of an interim analysis of the randomized phase III CANTON trial, which investigated concurrent and adjuvant temozolomide in patients with anaplastic glioma without a 1p/19q co-deletion.

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

July 26th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. Tolcher on Utomilumab Plus Pembrolizumab in Advanced Solid Tumors

July 25th 2016

Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics San Antonio, discusses a phase Ib study examining the combination of the 4-1BB agonist utomilumab (PF-05082566) and pembrolizumab (Keytruda) as a treatment for patients with advanced solid tumors.

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

July 25th 2016

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Dr. Oh on Recognizing Symptom Burden in Advanced Prostate Cancer

July 22nd 2016

William K. Oh, MD, professor of Medicine, Hematology, and Medical Oncology, and Urology, Mount Sinai Hospital, discusses a global study aimed at recognizing symptom burden in patients with advanced prostate cancer.

Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer

July 20th 2016

Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

July 19th 2016

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Dr. Rugo on SWISH Trial for HR-Positive Breast Cancer

July 18th 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Hellen Diller Family Comprehensive Cancer Center, discusses the results of the SWISH trial, which examined a dexamethasone-based mouthwash for the prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

July 15th 2016

Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC

July 14th 2016

Dr. Blum on Takeaways from ABC Trials for Breast Cancer

July 14th 2016

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

Dr. Nicholas Robert on MA.17R Trial for Patients With Early-Stage Breast Cancer

July 13th 2016

Nicholas J. Robert, MD, medical oncology, hematology, Virginia Cancer Specialists, US Oncology, discusses the MA.17R trial, which explored an extension of adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

July 12th 2016

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer

July 12th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.

Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

July 11th 2016

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).